Description: Lupin Limited, a pharmaceutical company, manufactures and distributes a range of branded and generic formulations, biotechnology products, active pharmaceutical ingredients, and specialty products in India, the United States, Japan, and internationally. The company offers formulations for use in the therapeutic areas of cardiovascular, diabetology, asthma, pediatrics, central nervous system, gastro-intestinal, anti-infective, non-steroidal anti-inflammatory drug therapy, anti-TB, and cephalosporin. It also develops and commercializes various drug delivery platforms; and provides biosimilar products. In addition, the company engages in the provision of the over-the-counter products, and contract manufacturing and supply services; and drug discovery and development programs in the therapeutic areas of oncology, immunology, and metabolic disorders, as well as bio clinical research activities. Lupin Limited has a licensing, development, and commercialization agreement with Boehringer Ingelheim for Lupin's MEK inhibitor compound (LNP3794) as a potential targeted therapy for patients with cancers. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001 as a result of its amalgamation with Lupin Laboratories Limited. Lupin Limited was founded in 1968 and is based in Mumbai, India.
Home Page: www.lupin.com
Officers
| Name | Title |
|---|---|
| Ms. Vinita D. Gupta | CEO & Exec. Director |
| Mr. Nilesh Deshbandhu Gupta | MD & Exec. Director |
| Mr. Ramesh Swaminathan | Global CFO, Head of Corp. Affairs & Exec. Director |
| Mr. Sunil Makharia | Pres of Fin. |
| Mr. Rajvardhan V. Satam | Company Sec. |
Exchange: BSE
Country: IN
Currency: Indian Rupee (INR)
| Forward PE: | 18.622 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.8783 |
| Price-to-Sales TTM: | 2.1915 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 18302 |